GSK (GSK) announced that efimosfermin, a once-monthly investigational liver therapy, has been granted Breakthrough Therapy Designation, BTE, by the US Food and Drug Administration, FDA, and Priority Medicines, PRIME, Designation by the European Medicines Agency, EMA, for the treatment of MASH. The two designations were supported by data from MASH patients with moderate to advanced and cirrhotic fibrosis
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s TESARO provides update on AnaptysBio litigation
- GSK Earnings this Week: How Will it Perform?
- Delaware court dismisses Tesaro breach of contract claim against AnaptysBio
- AnaptysBio price target lowered to $60 from $90 at UBS
- GSK says NMPA of China approved Blenrep with bortezomib, dexamethasone